Tadalafil + Placebo

Phase 3Terminated

1 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Muscular Dystrophy, Duchenne

Conditions

Muscular Dystrophy, Duchenne

Trial Timeline

Sep 1, 2013 → Mar 1, 2016

NCT ID

NCT01865084

About Tadalafil + Placebo

Tadalafil + Placebo is a phase 3 stage product being developed by Eli Lilly for Muscular Dystrophy, Duchenne. The current trial status is terminated. This product is registered under clinical trial identifier NCT01865084. Target conditions include Muscular Dystrophy, Duchenne.

What happened to similar drugs?

20 of 20 similar drugs in Muscular Dystrophy, Duchenne were approved

Approved (20) Terminated (3) Active (0)

✅GoserelinAstraZenecaApproved

✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Sugammadex 16 mg/kg + Neostigmine + Glycopyrrolate + Rocuronium + VecuroniumMerckApproved

✅Deep neuromuscular block + Moderate neuromuscular blockMerckApproved

✅Sugammadex + RocuroniumMerckApproved

✅sufficient dose of rocuronium + sugammadex 10 min after position changeMerckApproved

✅neostigmine/glycopyrrolate + sugammadexMerckApproved

✅Sugammadex 2 mg/kg + Sugammadex 4 mg/kg + Neostigmine + Glycopyrrolate + Neostigmine + AtropineMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01865084	Phase 3	Terminated	Sep 1, 2013	Mar 1, 2016	Muscular Dystrophy, Duchenne
NCT01460342	Phase 3	Completed	Dec 1, 2011	Oct 1, 2012	Benign Prostatic Hyperplasia
NCT01152190	Phase 3	Completed	Sep 1, 2010	Jul 1, 2012	Benign Prostatic Hyperplasia
NCT01130532	Approved	Completed	Aug 1, 2010	Jan 1, 2012	Erectile Dysfunction
NCT01026818	Approved	Completed	Nov 1, 2009	Oct 1, 2012	Erectile Dysfunction
NCT00848081	Phase 3	Completed	Mar 1, 2009	Dec 1, 2009	Benign Prostatic Hyperplasia
NCT00855582	Phase 3	Completed	Mar 1, 2009	Jul 1, 2010	Erectile Dysfunction
NCT00836693	Phase 3	Completed	Jan 1, 2009	Jan 1, 2010	Erectile Dysfunction
NCT00422734	Phase 3	Completed	Nov 1, 2006	Jan 1, 2008	Impotence
NCT00538564	Phase 2	Withdrawn	Nov 1, 2006	Aug 1, 2009	Sickle Cell Anemia
NCT00386009	Phase 2	Completed	Oct 1, 2006	May 1, 2008	Benign Prostatic Hyperplasia
NCT00547625	Phase 2	Completed	Oct 1, 2004	Jul 1, 2005	Prostatic Hyperplasia
NCT00382135	Approved	Completed	Nov 1, 2003	Dec 1, 2005	Erectile Dysfunction
NCT00381732	Phase 3	Completed	Oct 1, 2003	Jun 1, 2006	Erectile Dysfunction

Competing Products

20 competing products in Muscular Dystrophy, Duchenne

See all competitors

Product	Company	Stage	Hype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)	Biotrial	Phase 1/2	29
ENTR-601-44 + ENTR-601-44 - matching placebo	Entrada Therapeutics	Phase 1/2	29
ENTR-601-45 + ENTR-601-45 - matching placebo	Entrada Therapeutics	Phase 1/2	29
DS-5141b	Daiichi Sankyo	Phase 2	39
DS-5141b	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
scAAV9.U7.ACCA	Astellas Pharma	Phase 1/2	32
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mg	Astellas Pharma	Phase 2	35
LY2495655 + Placebo	Eli Lilly	Phase 2	35
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)	Jiangsu Hengrui Medicine	Phase 2	42
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + Rocuronium	Jiangsu Hengrui Medicine	Phase 2	42
HRS-9190 + HRS-9190 + HRS-9190	Jiangsu Hengrui Medicine	Phase 2	35
NS-065/NCNP-01	Nippon Shinyaku	Phase 2	35
Viltolarsen + Placebo	Nippon Shinyaku	Phase 3	40
Viltolarsen	Nippon Shinyaku	Phase 2	35
NS-089/NCNP-02 + NS-089/NCNP-02	Nippon Shinyaku	Phase 2	39
NS-065/NCNP-01	Nippon Shinyaku	Phase 1	29
NS-050/NCNP-03 + Placebo	Nippon Shinyaku	Phase 1/2	39
NS-089/NCNP-02	Nippon Shinyaku	Phase 2	42
Viltolarsen	Nippon Shinyaku	Phase 3	36